| Name | Title | Contact Details |
|---|
NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI).
SteadyMed Therapeutics, Inc. is a Specialty Pharmaceutical Company. SteadyMed leverages its PatchPump platform to develop its own therapeutic portfolio and partners to optimize the delivery of high volume (greater than two mL), high value, small molecule or biologic drugs. Our family of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner. SteadyMed aspires to redefine the parenteral therapeutics experience for patients dependent upon large doses of intravenous and subcutaneous medications: Extending the limits of parenteral therapeutics to restore freedom, joy and dignity to patients’ lives.
Apieron Biosystems is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.
Greatbatch, Inc. provides top-quality technologies to industries that depend on reliable, long-lasting performance through its brands Greatbatch Medical, Electrochem and QiG Group.